目的 探討磷酸化的哺乳動(dòng)物雷帕霉素靶蛋白(p-roTOR)在非小細(xì)胞肺癌(NSCLC) 中的表達(dá)及其對(duì)預(yù)后的預(yù)測(cè)價(jià)值。方法 運(yùn)用免疫組織化學(xué)EnVision法檢測(cè)59例NSCLC肺癌組織和10例非肺癌組織(3例肺結(jié)核和7例炎性假瘤)中p-mTOR蛋白的表達(dá)。結(jié)果 p-mTOR在肺 良性疾病組均為陰性，在NSCLC組織中表達(dá)的陽(yáng)性率為40.7％，顯著高于肺良性疾病組（χ2=6.237，P=0.013）；p-mTOR在NSCLC組織中的表達(dá)與性別、年齡和pTNM分期有關(guān)，而與其他臨床 病理參數(shù)(腫瘤大小、病理類型和淋巴結(jié)轉(zhuǎn)移情況)無(wú)明顯相關(guān)性。Kaplan-Meire生存分析顯示， p-mTOR與生存期無(wú)明顯相關(guān)(Log rank檢驗(yàn)P=0.055)。結(jié)論 檢測(cè)p-mTOR有助于肺部良惡性疾病的鑒別，單獨(dú)p-mTOR不能作為判斷NSCLC預(yù)后的參考指標(biāo)。
引用本文： 劉紅兵,宋勇,吳穎. p-mTOR在Ⅰ~Ⅲ期非小細(xì)胞肺癌組織中的表達(dá)及其與預(yù)后的關(guān)系. 中國(guó)呼吸與危重監(jiān)護(hù)雜志, 2008, 08(5): 354-357. doi: 復(fù)制
| 1. | Sabatini DM，Erdjument-Bromage H，Lui M，et al.RAFT1：a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.Cell，1994，78：35-43. |
| 2. | Brown EJ，Albers MW，Shin TB，et al.A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature，1994，369：756-758. |
| 3. | Balsara BR，Pei J，Mitsuuchi Y，et al.Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.Carcinogenesis，2004，25：2053-2059. |
| 4. | Herberger B，Puhalla H，Lehnert M，et al，Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.Clin Cancer Res，2007，13：4795-4799. |
| 5. | Gera JF，Mellinghoff IK，Shi Y，et al.AKT activity determines sensitivity to mammalian target of rapamycin（mTOR） inhibitors by regulating cyclin D1 and c-myc expression.J Biol Chem，2004，279：2737-2746. |
| 6. | Bjornsti MA，Houghton PJ.The TOR pathway：a target for cancer therapy.Nat Rev Cancer，2004，4：335-348. |
| 7. | Nave BT，Ouwens M，Withers DJ，et al.Mammalian target of rapamycin is a direct target for protein kinase B：identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.Biochem J，1999，344：427-431. |
| 8. | Sekulic A，Hudson CC，Homme JL，et al.A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.Cancer Res，2000，60：3504-3513. |
| 9. | Scott PH，Lawrence JC Jr.Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3–L1 adipocytes.J Biol Chem，1998，273：34496-34501. |
| 10. | Reynolds TH 4th，Bodine SC，Lawrence JC Jr.Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load.J Biol Chem，2002，277：17657-17662. |
| 11. | Sahin F，Kannangai R，Adegbola O，et al.mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms.Clin Cancer Res，2004，10：8421-8425. |
| 12. | Zhou X，Tan M，Stone Hawthorne V，et al.Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers.Clin Cancer Res，2004，10：6779-6788. |
| 13. | Faried LS，F(xiàn)aried A，Kanuma T，et al.Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.Oncol Rep，2006，16：57-63. |
| 14. | Kremer CL，Klein RR，Mendelson J，et al.Expression of mTOR Signaling PathwayMarkers in Prostate Cancer Progression.Prostate，2006，66：1203-1212. |
| 15. | Sieghart W，F(xiàn)uereder T，Schmid K，et al.Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.Transplantation，2007，83：425-432. |
| 16. | Atkins MB，Hidalgo M，Stadler WM，et al.Randomized phase II study of multiple dose levels of CCI-779，a novel mammalian target of rapamycin kinase inhibitor，in patients with advanced refractory renal cell carcinoma.J Clin Oncol，2004，22：909-918. |
| 17. | Witzig TE，Geyer SM，Ghobrial I，et al.Phase II trial of single-agent temsirolimus（CCI-779） for relapsed mantle cell lymphoma.J Clin Oncol，2005，23：5347-5356. |
| 18. | Galanis E，Buckner JC，Maurer MJ，et al.Phase II trial of temsirolimus（CCI-779） in recurrent glioblastoma multiforme：a North Central Cancer Treatment Group Study.J Clin On col，2005，23：5294-5304. |
| 19. | Chan S，Scheulen ME，Johnston S，et al.Phase II study of temsirolimus（CCI-779），a novel inhibitor of mTOR，in heavily pretreated patients with locally advanced or metastatic breast cancer.J Clin Oncol，2005，23：5314-5322. |
- 1. Sabatini DM，Erdjument-Bromage H，Lui M，et al.RAFT1：a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.Cell，1994，78：35-43.
- 2. Brown EJ，Albers MW，Shin TB，et al.A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature，1994，369：756-758.
- 3. Balsara BR，Pei J，Mitsuuchi Y，et al.Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.Carcinogenesis，2004，25：2053-2059.
- 4. Herberger B，Puhalla H，Lehnert M，et al，Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.Clin Cancer Res，2007，13：4795-4799.
- 5. Gera JF，Mellinghoff IK，Shi Y，et al.AKT activity determines sensitivity to mammalian target of rapamycin（mTOR） inhibitors by regulating cyclin D1 and c-myc expression.J Biol Chem，2004，279：2737-2746.
- 6. Bjornsti MA，Houghton PJ.The TOR pathway：a target for cancer therapy.Nat Rev Cancer，2004，4：335-348.
- 7. Nave BT，Ouwens M，Withers DJ，et al.Mammalian target of rapamycin is a direct target for protein kinase B：identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.Biochem J，1999，344：427-431.
- 8. Sekulic A，Hudson CC，Homme JL，et al.A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.Cancer Res，2000，60：3504-3513.
- 9. Scott PH，Lawrence JC Jr.Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3–L1 adipocytes.J Biol Chem，1998，273：34496-34501.
- 10. Reynolds TH 4th，Bodine SC，Lawrence JC Jr.Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load.J Biol Chem，2002，277：17657-17662.
- 11. Sahin F，Kannangai R，Adegbola O，et al.mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms.Clin Cancer Res，2004，10：8421-8425.
- 12. Zhou X，Tan M，Stone Hawthorne V，et al.Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers.Clin Cancer Res，2004，10：6779-6788.
- 13. Faried LS，F(xiàn)aried A，Kanuma T，et al.Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.Oncol Rep，2006，16：57-63.
- 14. Kremer CL，Klein RR，Mendelson J，et al.Expression of mTOR Signaling PathwayMarkers in Prostate Cancer Progression.Prostate，2006，66：1203-1212.
- 15. Sieghart W，F(xiàn)uereder T，Schmid K，et al.Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.Transplantation，2007，83：425-432.
- 16. Atkins MB，Hidalgo M，Stadler WM，et al.Randomized phase II study of multiple dose levels of CCI-779，a novel mammalian target of rapamycin kinase inhibitor，in patients with advanced refractory renal cell carcinoma.J Clin Oncol，2004，22：909-918.
- 17. Witzig TE，Geyer SM，Ghobrial I，et al.Phase II trial of single-agent temsirolimus（CCI-779） for relapsed mantle cell lymphoma.J Clin Oncol，2005，23：5347-5356.
- 18. Galanis E，Buckner JC，Maurer MJ，et al.Phase II trial of temsirolimus（CCI-779） in recurrent glioblastoma multiforme：a North Central Cancer Treatment Group Study.J Clin On col，2005，23：5294-5304.
- 19. Chan S，Scheulen ME，Johnston S，et al.Phase II study of temsirolimus（CCI-779），a novel inhibitor of mTOR，in heavily pretreated patients with locally advanced or metastatic breast cancer.J Clin Oncol，2005，23：5314-5322.